Insmed, Inc. $INSM Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC decreased its stake in Insmed, Inc. (NASDAQ:INSM) by 94.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,536 shares of the biopharmaceutical company’s stock after selling 75,131 shares during the period. Rice Hall James & Associates LLC’s holdings in Insmed were worth $789,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of INSM. Norges Bank acquired a new position in shares of Insmed in the 4th quarter valued at $506,625,000. Vanguard Group Inc. boosted its holdings in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter. Orbis Allan Gray Ltd acquired a new position in shares of Insmed in the 2nd quarter valued at $153,389,000. Finally, State Street Corp boosted its holdings in shares of Insmed by 30.6% in the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after buying an additional 1,217,390 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Mizuho set a $192.00 target price on shares of Insmed in a report on Tuesday. Wells Fargo & Company lowered their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Royal Bank Of Canada lowered their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Roth Mkm restated a “buy” rating on shares of Insmed in a report on Monday, June 8th. Finally, HC Wainwright restated a “buy” rating on shares of Insmed in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $211.86.

Insmed Stock Down 2.0%

Shares of NASDAQ:INSM opened at $95.52 on Wednesday. The stock has a market cap of $20.70 billion, a P/E ratio of -16.61 and a beta of 0.79. The firm has a fifty day moving average price of $121.91 and a 200 day moving average price of $149.36. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s quarterly revenue was up 229.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.42) EPS. Sell-side analysts predict that Insmed, Inc. will post -2.54 EPS for the current year.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 2,159 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $220,800.93. Following the sale, the insider owned 39,454 shares of the company’s stock, valued at approximately $4,034,960.58. This represents a 5.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 160,482 shares of company stock worth $24,438,193 in the last quarter. 2.10% of the stock is currently owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.